Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 11Phase NA 7Phase 1/2 6Phase 3 3Phase 4 1

Status

Completed 15Unknown 6Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1

Interventions

Metformin 3Letrozole 3Sperm Injections, Intracytoplasmic 2Progesterone 2Lidocaine 2Indocyanine Green 2Gentamicins 2Estradiol 2Clomiphene 2Bevacizumab 2Acitretin 2tirbanibulin 1technetium Tc 99m nanocolloid 1suvorexant 1pomalidomide 1pembrolizumab 1pasireotide 1nilotinib 1methylnaltrexone 1ledipasvir 1ixazomib 1gadolinium ethoxybenzyl DTPA 1gadofosveset trisodium 1exemestane 1encorafenib 1dolutegravir 1ceftolozane, tazobactam drug combination 1binimetinib 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Doxorubicin × Clear all
NCT02853500 2025-02-05

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

Dana-Farber Cancer Institute

Phase 4 Withdrawn
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡